Results 21 to 30 of about 4,011 (178)

Portopulmonary hypertension practice patterns after liver transplantation

Liver Transplantation, EarlyView., 2022
Abstract Portopulmonary hypertension (POPH) is a type of pulmonary arterial hypertension occurring exclusively in those with portal hypertensive liver disease. Liver transplantation (LT) can significantly improve outcomes. Current guidelines counsel against immediate adjustments to targeted therapy after LT and suggest routine echocardiography as ...
Arun Jose, Elizabeth J. Kopras, Shimul A. Shah, Jean M. Elwing   +3 more
wiley   +1 more source

Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells. [PDF]

PLoS ONE, 2018
Treprostinil is applied for pulmonary arterial hypertension (PAH) therapy. However, the mechanism by which the drug achieves its beneficial effects in PAH vessels is not fully understood.
Christopher Lambers, Christoph Kornauth, Felicitas Oberndorfer, Panja M Boehm, Michael Tamm, Walter Klepetko, Michael Roth   +6 more
doaj   +1 more source

Prenatal treprostinil reduces the pulmonary hypertension phenotype in the rat model of congenital diaphragmatic hernia

EBioMedicine, 2022
Summary: Background: Persistent pulmonary hypertension (PH) causes significant mortality and morbidity in infants with congenital diaphragmatic hernia (CDH).
Felix Rafael De Bie, Christopher Gates Halline, Travis Kotzur, Kevin Hayes, Christopher Copeland Rouse, Jonathan Chang, Abby Christine Larson, Sameer Ahmad Khan, Ashley Spina, Samantha Tilden, Francesca Maria Russo, Holly Lee Hedrick, Jan Deprest, Emily Anne Partridge   +13 more
doaj   +1 more source

The Use of Treprostinil for Bronchopulmonary Dysplasia Associated Pulmonary Hypertension. [PDF]

Pediatr Pulmonol
BACKGROUND: Treprostinil for the treatment of bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH) has previously been described in small cohort studies, often used later in the course after failure to improve on other therapies ...
Tsoi SM, Parker C, Colglazier E, Cheung S, Taleb M, Nawaytou H, Amin E, Fineman JR, Keller RL.   +8 more
europepmc   +2 more sources

Treprostinil reduces mitochondrial injury during rat renal ischemia-reperfusion injury [PDF]

, 2021
Background: Renal ischemia-reperfusion injury (IRI) is a major factor contributing to acute kidney injury and it is associated with a high morbidity and mortality if untreated.
Akhlaghi, Fatemeh, Ding, Meiwen, Ghonem, Nisanne S., Gohh, Reginald, Tolbert, Evelyn, Birkenbach, Mark   +5 more
core   +1 more source

Novel dose–response analyses of treprostinil in pulmonary arterial hypertension and its effects on six-minute walk distance and hospitalizations

Pulmonary Circulation, 2020
Treprostinil is a prostacyclin analogue approved for the treatment of pulmonary arterial hypertension. Apart from the inhaled formulation, there is neither a target dose nor a ceiling dose to guide clinicians using treprostinil; doses are individualized ...
Gautam Ramani, Steven Cassady, Eric Shen, Meredith Broderick, Allie Wasik, Qun Sui, Andrew Nelsen   +6 more
doaj   +1 more source

Real‐world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting

Pulmonary Circulation, 2022
Real‐world dosing and titration of parenteral (subcutaneous, SC; intravenous, IV) prostacyclin, a mainstay of pulmonary arterial hypertension (PAH) treatment, is not always consistent with prescribing information or randomized trials and has yet to be ...
Vijay P. Balasubramanian, Zeenat Safdar, Margaret R. Sketch, Meredith Broderick, Andrew C. Nelsen, Dasom Lee, Lana Melendres‐Groves   +6 more
doaj   +1 more source

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension

Respiratory Medicine Case Reports, 2022
There are no prospective studies or guidelines describing transition between selexipag and oral treprostinil. We present two different transition strategies from selexipag to oral treprostinil, one started inpatient and then completed at home, and one ...
Carlo Arevalo, R.James White, Daniel Lachant   +2 more
doaj   +1 more source

Intravenous Treprostinil in Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension Using Implantable Pumps—Single-Center Experience over More Than a Decade

Journal of Cardiovascular Development and Disease, 2023
The management of chronic thromboembolic pulmonary hypertension has significantly changed over the last decade with the availability of both specific therapies and interventional treatments.
Regina Steringer-Mascherbauer, Charlotte Huber, Uwe Fröschl, Dagmar Engleder, Reinhold Függer, Maria Lummersdorfer, Ralf Lenhard, Martin Martinek   +7 more
doaj   +1 more source

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension

Pulmonary Circulation, 2023
Treprostinil is a chemically stable analog of prostacyclin, and inhaled treprostinil was developed to deliver the effects directly to the pulmonary vasculature while minimizing systemic side effects.
Masataka Kuwana, Kohtaro Abe, Hideyuki Kinoshita, Hiromi Matsubara, Shun Minatsuki, Toyoaki Murohara, Seiichiro Sakao, Yuichiro Shirai, Nobuhiro Tahara, Ichizo Tsujino, Kenta Takahashi, Shingo Kanda, Takeshi Ogo   +12 more
doaj   +1 more source